Discrepancy over Suzhou Highfine Biotech's reported profits ...
Discrepancy over Suzhou Highfine Biotech's reported profits and lack of free cashflow over past year raises queries about its earnings power. Despite EPS growth in three years, potential risks and warning signs are noteworthy.
Suzhou Highfine Biotech's (SZSE:301393) Problems Go Beyond Weak Profit
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4014Followers
0Following
9010Visitors
Follow